Journal of Contemporary Brachytherapy (Dec 2017)

Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy: a case report

  • Flavio Giannelli,
  • Ilaria Chiola,
  • Liliana Belgioia,
  • Stefania Garelli,
  • Alice Pastorino,
  • Michela Marcenaro,
  • Serafina Mammoliti,
  • Sergio Costantini,
  • Nicolò Bizzarri,
  • Valerio Vellone,
  • Salvina Barra,
  • Renzo Corvò

DOI
https://doi.org/10.5114/jcb.2017.71554
Journal volume & issue
Vol. 9, no. 6
pp. 572 – 578

Abstract

Read online

Hidradenocarcinoma (HC) is a very rare disease. This case report illustrates a successful treatment of a 60-year-old woman with vulvo-vaginal localization of hidradenocarcinoma treated with external beam radiotherapy delivered by helical tomotherapy with a simultaneous integrated boost (SIB), followed by brachytherapy. External beam radiotherapy dose prescription was 50.4 Gy in 28 fractions, five fractions per week to whole pelvis (planning target volume 1 – PTV1), 60.2 Gy in 28 fractions to SIB1 (fundus of uterus and right inguinal node), and 58.8 Gy in 28 fractions to SIB2 (lower/middle third of vagina, paraurethral region and right inguinal lymph nodes). Brachytherapy dose prescription was 28 Gy in 4 fractions for cervix, fundus of uterus and upper third of vagina (HR-CTV1), and 22 Gy in 4 fractions to middle third of vagina and paraurethral region (HR-CTV2). D90 for whole treatment was 91.9 Gy and 86.0 Gy for HR-CTV1 and HR-CTV2, respectively. Patient remained 12-months disease-free without treatment related side effects.

Keywords